Voyager Therapeutics (NASDAQ:VYGR) Stock Rating Lowered by StockNews.com

Voyager Therapeutics (NASDAQ:VYGR) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Friday.

Several other analysts have also weighed in on VYGR. Wedbush initiated coverage on Voyager Therapeutics in a report on Friday, November 29th. They issued an “outperform” rating and a $11.00 target price on the stock. Leerink Partnrs raised shares of Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Leerink Partners assumed coverage on shares of Voyager Therapeutics in a research report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price target on the stock. Finally, Citigroup initiated coverage on shares of Voyager Therapeutics in a research note on Monday, December 2nd. They set a “buy” rating and a $12.00 price objective for the company. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $17.00.

Voyager Therapeutics Trading Up 0.3 %

Shares of VYGR opened at $6.27 on Friday. Voyager Therapeutics has a twelve month low of $5.19 and a twelve month high of $11.72. The firm has a market capitalization of $342.53 million, a P/E ratio of 8.83 and a beta of 0.90. The firm’s 50-day moving average is $6.59 and its two-hundred day moving average is $7.16.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The business had revenue of $24.63 million for the quarter, compared to analyst estimates of $12.63 million. During the same quarter in the previous year, the company earned ($0.59) EPS. Analysts predict that Voyager Therapeutics will post -0.89 EPS for the current year.

Insider Activity

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total transaction of $34,914.18. Following the sale, the insider now owns 86,001 shares in the company, valued at $500,525.82. This trade represents a 6.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 4.53% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

Several institutional investors have recently added to or reduced their stakes in VYGR. China Universal Asset Management Co. Ltd. boosted its stake in Voyager Therapeutics by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock worth $61,000 after buying an additional 4,098 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Voyager Therapeutics during the 2nd quarter worth about $85,000. Intech Investment Management LLC acquired a new stake in shares of Voyager Therapeutics in the third quarter worth approximately $74,000. Victory Capital Management Inc. grew its holdings in Voyager Therapeutics by 14.5% in the second quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock valued at $102,000 after purchasing an additional 1,630 shares during the period. Finally, Hsbc Holdings PLC purchased a new stake in Voyager Therapeutics in the second quarter valued at approximately $128,000. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.